Management of Overactive Bladder With Transdermal Oxybutynin

In clinical trials, transdermal oxybutynin (OXY-TDS) has shown comparable efficacy and improved tolerability when compared with conventional pharmacotherapy. Systemic anticholinergic adverse effects are comparable to those with placebo, most likely owing to avoidance of first-pass hepatic metabolism...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Starkman, Jonathan S, Dmochowski, Roger R
Формат: Artigo
Язык:Inglês
Опубликовано: MedReviews, LLC 2006
Предметы:
Treatment Update
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1578546/
https://ncbi.nlm.nih.gov/pubmed/17043706
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы